RxDoctor Payments Data

Hugh Xian, MD

Neurology · Islip, NYNPI 1790759918

Payments from drug & device makers

$6,738in general payments, 2019–2025

Across 385 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biohaven Pharmaceuticals, Inc.$444
  • Novartis$412
  • Amgen$306
  • Merz North America, Inc.$301
  • Lundbeck LLC$270
  • plus $2K from 35 others

What the payments were for

  • Speaking & faculty fees$701%
  • Food & beverage$6,63198%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,738 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$309,753
Medicare patients
635
Services billed
10,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4612$333,262
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$319,106
BotoxOnabotulinumtoxina72$81,422
Nurtec OdtRimegepant Sulfate64$77,491
QuliptaAtogepant39$46,606
AptiomEslicarbazepine Acetate11$28,758
Emgality PenGalcanezumab-Gnlm21$13,702
UbrelvyUbrogepant12$12,763
NeuproRotigotine12$9,891
Aimovig AutoinjectorErenumab-Aooe13$9,286
Memantine Hcl376$9,263
Sumatriptan Succ-Naproxen SodSumatriptan Succ/Naproxen Sod20$4,114
Pregabalin24$2,506
Levetiracetam80$1,211
Donepezil Hcl153$1,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$56$319,10616 claims
AbbVieBotox, Qulipta, Ubrelvy$2,615$140,791123 claims
UCB, Inc.Neupro$248$9,89112 claims
Upsher-smith Laboratories LLCTopiramate$32$9815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in Islip

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →